Biosimilar LA-EP2006 and Pegfilgrastim Equivalent in Efficacy, Safety in Prevention of Neutropenia in Breast Cancer

Share this content:
Proposed biosimilar LA-EP2006 and reference pegfilgrastim were comparable regarding efficacy and safety in the prevention of neutropenia.
Proposed biosimilar LA-EP2006 and reference pegfilgrastim were comparable regarding efficacy and safety in the prevention of neutropenia.

Proposed biosimilar LA-EP2006 and reference pegfilgrastim were comparable regarding efficacy and safety in the prevention of neutropenia in patients with early stage breast cancer receiving TAC, according to results of a study published in The Oncologist.1

Pegfilgrastim, which is used for the prevention of chemotherapy-induced neutropenia, has no approved biosimilar. Researchers conducted the phase 3, randomized, double-blind PROTECT-2 trial to compare LA-EP2006 with reference pegfilgrastim in patients with early stage breast cancer receiving adjuvant or neoadjuvant myelosuppressive  chemotherapy.

A total of 308 patients were randomly assigned to receive LA-EP2006 or pegfilgrastim. Each received TAC (intravenous docetaxel 75 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2 on day 1 of each cycle, for 6 or more cycles. Pegfilgrastim or the biosimilar were administered subcutaneously (6 mg in 0.6 mL) on day 2 of each cycle.

The primary endpoint was duration of severe neutropenia (DSN) during cycle 1 (number of consecutive days with an absolute neutrophil count <0.5 × 109/L), with equivalence confirmed if 90% and 95% confidence intervals were within a 1-day margin.

RELATED: Neoadjuvant T-DM1 Plus Pertuzumab May Improve HER+ Breast Cancer Outcomes

Results showed that DSN was equivalent between the groups at mean ± SD 1.36 ± 1.13 (LA-EP2006, n = 155) and 1.19 ± 0.98 (reference, n = 153) in cycle 1. With a treatment difference (reference minus LA-EP2006) of −0.16 days (90% CI, −0.36 to 0.04; 95% CI, −0.40 to 0.08), LA-EP2006 was equivalent to reference pegfilgrastim. Secondary efficacy parameters were similar between groups across cycles. Safety profiles were also similar. No neutralizing antibodies against pegfilgrastim, filgrastim, or polyethylene glycol were detected.

Reference

  1. Blackwell K, Donskih R, Jones CM, et al. A comparison of proposed biosimilar LA-EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: pegfilgrastim randomized oncology (supportive care) trial to evaluate comparative treatment (PROTECT-2), a phase III, randomized, double-blind trial [published online ahead of print April 18, 2016]. Oncologist. doi: 10.1634/theoncologist.2016-0011.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters